Spyre Therapeutics (SYRE) Operating Income (2015 - 2026)
Spyre Therapeutics (SYRE) posted Operating Income of -$45.6 million for Q1 2026, up 20.17% on a QoQ basis from -$57.2 million in Q4 2025, and up 14.8% year-over-year from -$39.8 million in Q1 2025.
Spyre Therapeutics (SYRE) Operating Income (2015 - 2026) Analysis & Trends
Spyre Therapeutics' Operating Income history runs 12 years deep, the most recent figure standing at -$45.6 million for Q1 2026.
- Quarterly Operating Income rose 14.8% year-over-year to -$45.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$201.6 million (up 5.94% YoY) and the FY2025 annual result came in at -$209.6 million, changed 0.48% from the prior year.
- Operating Income was -$45.6 million for Q1 2026 at Spyre Therapeutics, up from -$57.2 million in the prior quarter.
- Across five years, Operating Income topped out at -$18.3 million in Q3 2023 and bottomed at -$159.2 million in Q2 2023.
- A 5-year average of -$46.5 million and a median of -$45.6 million in 2026 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2023 — Operating Income tumbled 610.19% — and 2024, when it surged 72.28%.
- Spyre Therapeutics' Operating Income stood at -$19.2 million in 2022, then slumped by 139.61% to -$45.9 million in 2023, then plunged by 33.41% to -$61.3 million in 2024, then advanced by 6.66% to -$57.2 million in 2025, then climbed by 20.17% to -$45.6 million in 2026.
- Business Quant data shows SYRE's Operating Income at -$45.6 million in Q1 2026, -$57.2 million in Q4 2025, and -$56.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 249.90 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.72 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -445.22 Mn |
| 10 | Spyre Therapeutics | 257.83 Mn | 257.83 Mn | - | -45.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -45.64 Mn |
| Dec 31, 2025 | -57.17 Mn |
| Sep 30, 2025 | -56.89 Mn |
| Jun 30, 2025 | -41.94 Mn |
| Mar 31, 2025 | -53.57 Mn |
| Dec 31, 2024 | -61.25 Mn |
| Sep 30, 2024 | -55.39 Mn |
| Jun 30, 2024 | -44.15 Mn |
| Mar 31, 2024 | -47.77 Mn |
| Dec 31, 2023 | -45.91 Mn |
| Sep 30, 2023 | -18.34 Mn |
| Jun 30, 2023 | -159.25 Mn |
| Mar 31, 2023 | -18.81 Mn |
| Dec 31, 2022 | -19.16 Mn |
| Sep 30, 2022 | -18.76 Mn |
| Jun 30, 2022 | -22.42 Mn |
| Mar 31, 2022 | -24.44 Mn |
| Dec 31, 2021 | -20.44 Mn |
| Sep 30, 2021 | -20.29 Mn |
| Jun 30, 2021 | -6.71 Mn |